Inherited alleles account for most of the genetic risk for schizophrenia. However, new (de novo) mutations, in the form of large chromosomal copy number changes, occur in a small fraction of cases and disproportionally disrupt genes encoding postsynaptic proteins. Here we show that small de novo mutations, affecting one or a few nucleotides, are overrepresented among glutamatergic postsynaptic proteins comprising activity-regulated cytoskeleton-associated protein (ARC) and N-methyl-D-aspartate receptor (NMDAR) complexes. Mutations are additionally enriched in proteins that interact with these complexes to modulate synaptic strength, namely proteins regulating actin filament dynamics and those whose messenger RNAs are targets of fragile X mental retardation protein (FMRP). Genes affected by mutations in schizophrenia overlap those mutated in autism and intellectual disability, as do mutation-enriched synaptic pathways. Aligning our findings with a parallel case-control study, we demonstrate reproducible insights into aetiological mechanisms for schizophrenia and reveal pathophysiology shared with other neurodevelopmental disorders.
Schizophrenia is a disorder whose pathophysiology is largely unknown. It has a lifetime risk of about 1%, is frequently chronic and socially disabling, and is associated with an average reduction in lifespan of about 25 years. High heritability points to a major role for transmitted genetic variants 1 . However, it is also associated with a marked reduction in fecundity 2 , leading to the hypothesis that alleles with large effects on risk might often occur de novo (mutations present in affected individual but not in either parent) to balance their elimination from the population by selection 3 . Of the known risk alleles for schizophrenia, the only ones definitively shown to confer considerable increments in risk are rare chromosomal copy number variants (CNVs) 1, 4 , which involve deletion or duplication of thousands of bases of DNA. As predicted by the association of schizophrenia with decreased fecundity, these CNVs often occur de novo in the small proportion of cases in which they are found 5 . Exome sequencing technology now allows systematic scans of genes for de novo mutations at single-base rather than kilobase resolution. This approach has already implicated de novo loss-of-function mutations in disorders in which, as in schizophrenia, de novo CNVs have a role, including autism spectrum disorder (ASD) [6] [7] [8] [9] and intellectual disability 10, 11 . In schizophrenia, the results from exome sequencing [12] [13] [14] do not yet support definitive conclusions, probably owing to limited sample sizes.
We report the largest exome sequencing study of de novo mutations in schizophrenia to date, using genomic (blood) DNA from 623 schizophrenia trios. The primary aims were fourfold (Table 1a-d). The first two aims were to establish a general case for the relevance of de novo mutations in schizophrenia by determining whether de novo mutations affecting protein sequences occur in schizophrenia at higher than expected rates (Table 1a) or are enriched among sets of genes implicated in the disorder through other approaches (Table 1b) . The remaining two aims, the main motivation for the study, were to determine whether de novo mutations implicate specific pathogenic biological processes in schizophrenia (Table 1c) and to investigate the relationship between schizophrenia and other neurodevelopmental disorders (Table 1d ). To test for reproducibility, and ensure robustness of the findings to study design, we shared our findings with an independent case-control exome sequencing study 15 .
De novo mutation rates
We generated sequence data for a median of 93% of targeted exome bases at a depth of .10 reads, from which we generated putative de novo calls (Extended Data Figs 1 and 2; Supplementary Information). Using Sanger sequencing, we validated 637 de novo coding or canonical splice site variants (Supplementary Table 1 ) in 617 probands (6 trios were excluded after quality control), a rate of 1.032 mutations per trio. These comprised 482 nonsynonymous mutations, of which 64 were loss-offunction (nonsense, splice and frameshift). The remaining 155 mutations were silent and were therefore excluded from enrichment analyses.
The exome point-mutation rate in schizophrenia was, adjusting for target coverage, 1.61 3 10 28 per base per generation, compatible with the population expectation of 1.64 3 10 28 (Supplementary Information). The mutation rate (corrected for experimental confounders, Supplementary Information) was associated with increasing paternal (P 5 0.005) and maternal (P 5 0.0003) age at proband birth. Given the high correlation between the two, we could not confidently distinguish independent parental age effects (Supplementary Information). As expected 16 , most de novo mutations (79%) we could phase occurred on paternal chromosomes (Supplementary Information). The number of de novo mutations per individual followed a Poisson distribution (Extended Data Fig. 3a ), in line with previous studies of autism 6 and schizophrenia 13 . Nevertheless, loss-of-function de novo mutations were more common in patients with relatively poor school performance (P 5 0.018; Extended Data Fig. 3b ), but none of the other variables tested-family history, age at onset, gender or having a de novo CNV-were significantly associated with mutation rates.
Compared with 731 controls from published data sets (Supplementary Table 2 ), probands did not have a significant elevation in the relative rates of nonsynonymous to silent mutations, or loss-of-function to missense mutations (Tables 1a and 2 ). No differences were observed between schizophrenia cases with or without de novo CNVs or between those stratified by common allele risk scores (Extended Data Table 1a ). Consistent with their higher loss-of-function mutation rate, those with school grades below the median had significantly elevated loss-of-function to missense ratios compared to both controls (P 5 0.02) and cases with higher school grades (P 5 0.0095) (Extended Data Table 1b and Extended Data Fig. 3b ). In the absence of an effect of age at onset (that might affect school performance), this suggests loss-of-function mutations occur preferentially in (the large proportion of) schizophrenia cases that have premorbid cognitive impairment 17 . All probands attended and graduated from mainstream schools, which excluded people with significant degrees of intellectual disability; moreover, recruiting psychiatrists were explicitly instructed to exclude people with known intellectual disability. Thus, the enrichment of loss-of-function mutations in those with the poorest scholastic attainment cannot be attributed Table 5 0.27 0.02
Hypotheses are grouped into four broad categories (a-d). Each is comprised of sub-tests from which we derive global evidence for the broad category (see Supplementary Information) . a, The broad P value was generated using Fisher's exact method on the missense, silent and loss-of-function mutation counts. b, P values were generated using Fisher's combined probability test to combine the sub-tests. Counts of de novo mutation in the present study, in previous studies of schizophrenia (refs 13 and 14) , and in all studies of schizophrenia combined (Schizophrenia all), which includes this study and an additional small study 12 . Controls are unaffected individuals or unaffected siblings of probands with autism spectrum disorder or schizophrenia. To control for factors that influence estimates of absolute rates (sequencing depth, calling, parental age, etc.), we tested for differences between the ratios of classes of de novo mutations (nonsynonymous to silent, loss-of-function to missense) in the disorder groups and the controls, using Fisher's exact test. Nominally significant P values (, 0.05) are bold.
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to the inclusion of individuals with severe intellectual disability, although this does not preclude the presence of individuals with mild intellectual disability among cases with low educational achievement.
Mutations in schizophrenia gene sets
Gene sets selected for independent evidence for relevance to schizophrenia showed enrichment (P corrected 5 0.0007) of nonsynonymous de novo mutations (Table 1b ), indicating that a proportion of mutations are pathogenic for schizophrenia. Specifically, genes were recurrent for de novo mutations more than expected (Table 1b, Extended  Data Table 2 ). Genes affected by nonsynonymous de novo mutations were also enriched for inherited rare risk alleles (Table 1b) , with excess transmission of rare nonsynonymous alleles from parents to the affected probands, as well as enrichment in cases of rare (minor allele frequency (MAF) , 0.001) gene-disruptive mutations in an independent case-control exome sequencing study 15 . One gene, TAF13, encoding a subunit of the TFIID transcription initiation complex, contains two de novo loss-of-function mutations. This recurrence is significant even after genome-wide correction (P 5 1 3 10
26
; P corrected 5 0.024) (Extended Data Table 2 ). Replication is necessary to firmly establish this as a susceptibility gene.
Mutations enriched in synaptic genes
Previous studies have suggested that CNVs in people with schizophrenia preferentially affect broadly defined sets of synaptic genes 18, 19 . Moreover, a detailed analysis of de novo CNVs based on gene sets constructed from experimental proteomics led us to propose that this synaptic enrichment could be explained by mutations affecting proteins closely associated with the N-methyl-D-aspartate (NMDA) receptor, which we refer to as the NMDAR complex, and proteins that interact with ARC (activity-regulated cytoskeleton-associated protein), referred to as the ARC complex 20 . Our primary functional hypothesis in the present study was that genes encoding proteins in the ARC and NMDAR complexes would be disproportionately affected by de novo SNV and indel mutations. We additionally postulated that brain-expressed genes that are repressed by fragile X mental retardation protein (FMRP) 21 would also be enriched for de novo mutations because these have been shown to be enriched for de novo mutations in ASD 9 . Moreover, FMRP targets include multiple members of the NMDAR and ARC complexes.
We observed experiment-wide significant enrichment for nonsynonymous mutations among the synaptic gene sets (Table 1c) , as well as specifically for NMDAR and ARC complexes (Tables 1c and 3 , Extended Data Fig. 4 ). NMDAR and ARC complexes are closely associated elements central to regulating synaptic strength at glutamatergic synapses and have been implicated in cognition. NMDA signalling triggers multiple processes required for inducing synaptic plasticity 22 . ARC is involved in almost all known forms of synaptic plasticity, including synaptic remodelling, the consolidation of changes in synaptic strength linked to memory and response to stress [23] [24] [25] , and regulating synapse elimination during development 26 , a process believed to be aberrant in schizophrenia 27 . FMRP targets were also enriched for nonsynonymous de novo mutations (Table 1c) , even after NMDAR, ARC and the broader group of postsynaptic density genes were removed (Extended Data Table 3 ). Given that loss of FMRP results in widespread deficits in synaptic plasticity 28 , these findings again implicate pathogenic disruption of plasticity mechanisms in schizophrenia. Secondary analyses to dissect the FMRP target enrichment by subdividing genes by gene ontology 29 membership did not identify significant categories.
Support for the candidate hypotheses were replicable and robust to study design. In the schizophrenia case-control study 15 , rare (MAF , 0.001) loss-of-function mutations were enriched in NMDAR (P 5 0.02), ARC (P 5 1 3 10 23 ), and FMRP target (P 5 0.003) sets. Across studies, lossof-function enrichments in the ARC complex were particularly striking; 17-fold here (Table 3 and Extended Data Fig. 4f ) and 19-fold in the case-control study, indicating that disruption of ARC function has particularly strong effects on disease risk.
Aiming to identify hitherto unsuspected disease mechanisms, we undertook an hypothesis-free analysis based on the comprehensive gene ontology (GO) annotations 29 . A single category (GO:0051017) was significantly enriched for nonsynonymous de novo mutations (P 5 6.63 10
26
) after correction for all GO categories (P corrected 5 0.032). Genes in GO:0051017, assembly of actin filament bundles, are intimately involved in synaptic plasticity, and are functionally interconnected with ARC and NMDAR signalling (see Supplementary Information). Even after removal of genes overlapping with ARC/NMDAR sets, GO:0051017 remained enriched eightfold for mutations (P 5 0.0011). Although not significant in the case-control data set 15 , this category was significantly enriched for de novo CNVs in a study of ASD 30 . It also includes KCTD13, the gene responsible for some of the phenotypes associated with CNVs at 16p11.2 (ref. 31) , duplication of which is a risk factor for schizophrenia 4 . KCTD13 also maps to a schizophrenia genome-wide significant SNP locus 32 .
Connectivity of mutated synaptic genes
Seeking further insights into synaptic pathology, we identified interactions involving proteins with de novo mutations using a synaptic interactome database 33 (Supplementary Information). Proteins with nonsynonymous de novo mutations had more connectivity than expected among each other (Fig. 1a) and with synaptic proteins in general, indicating a greater than average importance to the synapse. Directly interacting proteins with de novo mutations are involved in multiple processes regulating synaptic plasticity, particularly NMDA, AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and kainate Table 2 . Total numbers of mutations for each class in each sample are given in parentheses. Additional details for the current study, including genes and 95% credible intervals (CI) for the O/E statistics, are given in Extended Data Fig. 4 .
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receptor trafficking, and the regulation of actin dynamics. These interactions involve genes not present in our pre-assigned NMDAR/ARC and actin filament complexes (Supplementary Information). Although our analyses highlighted postsynaptic processes, some of the interacting synaptic proteins with de novo mutations are presynaptic (Fig. 1a , Supplementary Information and Extended Data Fig. 4a ). Pre-and postsynaptic proteins are, however, closely functionally related; indeed, transsynaptic effects of presynaptic proteins on the regulation of AMPA receptor trafficking and NMDAR-dependent plasticity have recently been described 34 . We were unable to replicate a previous report of prenatal bias in brain expression for genes with schizophrenia de novo mutations 13 using microarray or RNA-seq data (Supplementary Information and Extended Data Table 4 ).
Overlaps between disorders
CNV loci associated with schizophrenia overlap with those seen in ASD, intellectual disability and attention deficit hyperactivity disorder 1, 4, 35 . However, because pathogenic CNVs typically span multiple genes and are concentrated in a relatively small fraction of the genome 36 , it is possible that this may not indicate cross-disorder effects at the level of specific genes. Therefore, we sought evidence for shared genetic aetiology between schizophrenia and both intellectual disability and ASD 37 by testing for overlap of genes affected by de novo mutations in schizophrenia, ASD and intellectual disability.
Genes with de novo mutations in the current study overlapped those affected by de novo mutations in ASD 6-9 and intellectual disability 10, 11 ( Fig. 1b and Tables 1d and 4), but not in controls (Extended Data mutations are noted with a red outline. Proteins with nonsynonymous de novo mutations had more than expected direct interconnections (P 5 0.008), which was consistent with more overall connectivity to synaptic proteins as a whole (P 5 0.005). b, Overlap of genes bearing nonsynonymous (NS) de novo mutations in schizophrenia (refs 12-14) , autism spectrum disorder (refs 6-9) and intellectual disability (refs 10, 11). Overlaps of six or fewer genes are listed by name. See Extended Data Table 5 for statistical significance of these overlaps, and see Table 2 and text for disease sets. Table 2 . Additional comparisons are given in Extended Data Table 5 .
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even in the small subset of genes (N 5 7) with recurrent loss-of-function de novo mutations in ASD (P 5 0.0018) or intellectual disability (P 5 0.019), the mutations occurring in SCN2A (encoding an alpha subunit of voltage-gated sodium channels, a major mediator of neuronal firing and action potential propagation) and POGZ (whose involvement in mitosis suggests a possible role in regulating neuronal proliferation 38 ). Both SCN2A and POGZ are now established ASD genes 39 . Other notable genes affected by loss-of-function mutations in the present study for which there is prior support for loss-of-function mutations in other neurodevelopmental disorders include DLG2 and SHANK1 (Supplementary Information). Thus, we now show overlap between schizophrenia, ASD and intellectual disability at the resolution not just of loci or even individual genes, but even of mutations with similar functional (lossof-function) effects.
ARC/NMDAR complexes (Table 3 ) and FMRP targets (Extended Data Table 3 ) were enriched for de novo mutations in intellectual disability, and NMDAR and FMRP targets were also enriched in ASD, providing further evidence of shared disease mechanisms. However, we also find differences between the disorders. In general, enrichment statistics were stronger for ASD and intellectual disability than schizophrenia, particularly for loss-of-function mutations (Table 2) , despite the relatively small number of intellectual disability trios. Genes and mutation sites were most highly conserved in intellectual disability, then ASD, with schizophrenia least conserved (Supplementary Information and Extended Data Table 6 ). These findings indicate that highly disruptive mutations have a relatively lesser role in schizophrenia, and also that the disorders differ by severity of functional impairment, consistent with the hypothesis of an underlying gradient of neurodevelopmental pathology 40 indexed by cognitive impairment, with intellectual disability at one extreme.
That the most damaging mutations reflect a gradient of neurodevelopmental impairment is further supported by the observation that, within schizophrenia, the highest rate of loss-of-function mutations (Extended Data Fig. 3b ) occurred in individuals likely to have the greatest cognitive impairment (lowest scholastic attainment), as does the observation that the loss-of-function genic overlap between schizophrenia and both autism and intellectual disability is dependent on the de novo mutations (including SCN2A and POGZ) in those individuals (Extended Data Table 1c ). However, as noted above, the enrichment of loss-of-function mutations in those with the poorest scholastic attainment cannot be attributed to the inclusion of individuals with severe intellectual disability. Moreover, when we exclude cases with low scholastic attainment, we still see significant enrichment of the synaptic pathways that are enriched in the full sample (Supplementary Information  and Extended Data Table 1c ). Thus, our implication of synaptic protein complexes is not dependent on mutations present in a subset of cases with severely impaired cognitive function.
Discussion
In the largest exome-sequencing-based study of de novo mutations in schizophrenia, we demonstrate a convergence of de novo mutations on multiply defined sets of functionally related proteins, pointing to the regulation of plasticity at glutamatergic synapses as a pathogenic mechanism in schizophrenia. How disruption of these synaptic mechanisms affects brain function to produce psychopathology cannot be answered by genetic studies alone, but our identification of de novo mutations in these gene sets provides the basis to address this. Our findings of overlaps between the pathogenic mechanisms underlying schizophrenia and those in autism and intellectual disability lend support to recent, controversial suggestions that our understanding of these disorders might be advanced better by research that integrates findings across multiple disorders and places more emphasis on domains of psychopathology (for example, cognition) and their neurobiological substrates rather than current diagnostic categories 40, 41 .
METHODS SUMMARY
Parent proband trios (N 5 623), where the proband had a history of hospitalization for schizophrenia or schizoaffective disorder, were recruited from psychiatric hospitals in Bulgaria. Probands attended mainstream schools which excluded people with intellectual disability; all graduated with a pass. Exome DNA was captured from genomic DNA (whole blood), using either Agilent or NimbleGen array-based capture, and subjected to paired-end sequencing on Illumina HiSeq sequencers. The BWA-Picard-GATK pipeline was used for sequence alignment and variant calling. Putative de novo mutations were identified using Plink/Seq (http://atgu. mgh.harvard.edu/plinkseq) and were validated using Sanger sequencing. We used Plink/Seq to annotate mutations according to RefSeq gene transcripts (UCSC Genome Browser, http://genome.ucsc.edu). Mutation rate was tested for association with clinical and other covariates using a generalized linear model. Rates of functional classes of mutations in probands were compared with those in published controls using Fisher's exact test. Mutations were tested for recurrence, enrichment in candidate gene sets, and enrichment in genes affected by de novo mutations in previous studies using the dnenrich software (Supplementary Information, https:// bitbucket.org/statgen/dnenrich). dnenrich calculates one-sided P values under a binomial model of greater than expected hits using randomly placed mutations accounting for gene size, sequencing coverage, tri-nucleotide contexts and functional effects of the observed mutations. Candidate gene sets and studies of neuropsychiatric disease are described in the main and Supplementary Information. Primary hypotheses (Table 1) were Bonferroni-corrected for multiple testing.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
Extended Data Figure 2 | Metrics for de novo variants across cohorts and trios. a, Rates of recurrence of validated de novo mutations for tri-nucleotide sequences. For each of 96 possible tri-nucleotide base contexts of single-base mutations (accounting for strand symmetry by reverse complementarity), the number of observed de novo SNV is plotted (sorted by this count). Mutation counts are sub-divided into those not found in external data (red), those found in dbSNP (build 137, green), those found in controls (N 5 2543) in the parallel exome sequencing study 15 (cyan), and those found both in dbSNP and that study (purple). b, Comparison of on-target heterozygous SNV and indel call rate with putative de novo mutation calls. For each proband (N 5 623), the number of heterozygous SNV and indel calls is compared with the number of putative de novo mutations (child heterozygous, both parents homozygous reference). Probands are coloured by sequencing centre (see Supplementary Information for differences in exome capture), and six trios are noticeable outliers from all others (marked by '3') in terms of number of putative de novo mutations. c, Variation in sequencing coverage between and across trios and sequencing centres. For each trio (N 5 623), the number of bases covered by 10 reads or more for each member (marked by '3') and the joint coverage 9 in all three members (marked by points) are plotted at corresponding horizontal points; trios are sorted in increasing order of joint coverage and coloured by sequencing centre (see Supplementary Information) . The intersection of each exome capture with the RefSeq coding sequence is marked by respective dotted lines. ). Individuals were additionally split based on the presence of a 'pathogenic' CNV. A 'pathogenic' CNV was defined as either a de novo CNV identified for these samples in ref. 20 , or a CNV associated with psychiatric disease 1 . P values were computed using Fisher's exact test as in Table 2 . b, Ratios of NS:S and LoF:missense de novo mutations were compared (Fisher's exact test) between schizophrenia probands with poor scholastic performance and (1) controls; (2) probands with high scholastic performance. Nominally significant results (P , 0.05) are marked in bold. c, Enrichment of de novo mutations (as calculated by dnenrich, see Supplementary Information) including all individuals, after excluding individuals with the lowest scholastic achievement (a school grade of 3), or excluding those with a 'pathogenic' CNV (see above) or a polygenic score in the top 5% of the distribution (see above). These secondary exclusion analyses were performed on those gene sets identified as significant in the analyses of the full set; statistics shown as in Table 3 Enrichment was tested using dnenrich (Supplementary Information). Columns are as in Table 3 , and P , 0.05 are marked in bold. PSD, postsynaptic density.
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